Literature DB >> 21617536

Meibomian gland therapeutic expression: quantifying the applied pressure and the limitation of resulting pain.

Donald R Korb1, Caroline A Blackie.   

Abstract

OBJECTIVES: The purposes of this study were to determine (1) the pressure required to express the first nonliquid material from nonfunctional lower lid meibomian glands, (2) the pressure required to evacuate all of the expressible material from the glands (simulating the authors' methodology for therapeutic meibomian gland expression), and (3) the level of pain associated with these procedures.
METHODS: All patients (n=28) were recruited from those presenting for ocular examinations at a single practice. Custom instrumentation exerting pressures from 1.0 to 150.0 psi was developed to quantify the pressure applied during expression. The instrument was applied to the inner surface of the lower lid. The lid was then compressed between the thumb and the contact surface of the instrument. The applied pressure was displayed on a digital meter. The first procedure evaluated the pressure required to obtain the first nonliquid material from nonfunctional glands. The second evaluated the pressure required for evacuating all expressible gland contents. The pain response was monitored throughout the procedure.
RESULTS: The pressure to obtain the first nonliquid material ranged from 5 to 40 psi (mean=16.1±8.2 psi) and for the evacuation of expressible contents, from 10 to 40 psi (mean=25.6±11.4 psi). Only 7% of the patients could tolerate the pressure necessary to administer complete therapeutic expression along the entire lower eyelid.
CONCLUSIONS: Forces of significant magnitude are required for therapeutic expression. Pain is the limiting factor for the conduct of this treatment.

Entities:  

Mesh:

Year:  2011        PMID: 21617536     DOI: 10.1097/ICL.0b013e31821bc7c5

Source DB:  PubMed          Journal:  Eye Contact Lens        ISSN: 1542-2321            Impact factor:   2.018


  14 in total

Review 1.  A Review of Management Strategies for Nociceptive and Neuropathic Ocular Surface Pain.

Authors:  Harrison Dermer; Daniella Lent-Schochet; Despoina Theotoka; Christian Paba; Abdullah A Cheema; Ryan S Kim; Anat Galor
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

2.  Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study.

Authors:  Rolando Toyos; William McGill; Dustin Briscoe
Journal:  Photomed Laser Surg       Date:  2015-01       Impact factor: 2.796

3.  The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye.

Authors:  Caroline A Blackie; Christy A Coleman; Edward J Holland
Journal:  Clin Ophthalmol       Date:  2016-07-26

4.  Evaluation of the Safety and Effectiveness of Intense Pulsed Light in the Treatment of Meibomian Gland Dysfunction.

Authors:  Xiaodan Jiang; Huibin Lv; Hang Song; Mingzhou Zhang; Yan Liu; Xiaodan Hu; Xuemin Li; Wei Wang
Journal:  J Ophthalmol       Date:  2016-06-20       Impact factor: 1.909

5.  Effect of Intense Pulsed Light Therapy on Tear Proteins and Lipids in Meibomian Gland Dysfunction.

Authors:  Salwa Abdelkawi Ahmed; Ibraheim Mohi Eldin Taher; Dina Fouad Ghoneim; Abd Elhakim Mohamed Safwat
Journal:  J Ophthalmic Vis Res       Date:  2019 Jan-Mar

6.  Intense pulsed light plus meibomian gland expression versus intense pulsed light alone for meibomian gland dysfunction: A randomized crossover study.

Authors:  Kyoung Yoon Shin; Dong Hui Lim; Chan Hee Moon; Byung Jin Kim; Tae-Young Chung
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

Review 7.  Efficacy and safety of a vectored thermal pulsation system (Lipiflow®) in the treatment of meibomian gland dysfunction: a systematic review and meta-analysis.

Authors:  Jindong Hu; Sixing Zhu; Xinquan Liu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-08-10       Impact factor: 3.117

Review 8.  Emerging treatment options for meibomian gland dysfunction.

Authors:  Jing Qiao; Xiaoming Yan
Journal:  Clin Ophthalmol       Date:  2013-09-09

9.  Association Between Serum Levels of Testosterone and Estradiol With Meibomian Gland Assessments in Postmenopausal Women.

Authors:  Anna F Ablamowicz; Jason J Nichols; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-02       Impact factor: 4.799

Review 10.  Non-pharmaceutical treatment options for meibomian gland dysfunction.

Authors:  Reiko Arita; Shima Fukuoka
Journal:  Clin Exp Optom       Date:  2020-01-13       Impact factor: 2.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.